Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-acetyl-p-benzoquinone imine (NAPQI) is the principal reactive metabolite formed during acetaminophen metabolism. Generated by cytochrome P450 oxidation, NAPQI is highly electrophilic and binds covalently to cellular thiols, especially glutathione. At therapeutic doses, NAPQI is rapidly detoxified by conjugation with glutathione, but in overdoses or compromised detoxification, buildup of NAPQI causes extensive hepatic and cellular protein damage, leading to hepatotoxicity. NAPQI and related reactive metabolites also interact with hepatic enzymes such as thioredoxin reductase, further contributing to oxidative stress and liver injury. The metabolites can sensitize and activate TRPV1 channels, potentially influencing analgesic and cytotoxic effects. Drug interventions focus on preventing or reversing NAPQI toxicity by replenishing glutathione reserves or modulating its formation.
Toxic metabolites covalently bind to and damage hepatic proteins and enzymes (e.g., glutathione, thioredoxin reductase)\nCause cell death by depleting cellular antioxidants\nSensitize and activate TRPV1 channels
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-acetyl-p-benzoquinone imine (NAPQI) (NAPQI).